The Information in this section is intended for healthcare professionals only.

Please confirm that you are a healthcare professional.

The Information in this section is intended for healthcare professionals only.

Please confirm that you are a healthcare professional.

Cookies

This site uses cookies for site interaction analysis with a purpose of service quality enhancing and uninterrupted site work. More details in Cookies Policy
Accept
17 June 2024

Darnytsia has Presented Investment Projects at the International Ukraine Recovery Conference

17 June 2024

Darnytsia Pharmaceutical Company joined the International Ukraine Recovery Conference - 2024, which took place on June 11-12 in Berlin (Germany).

As part of the Government’s investment guide for international donors, Darnytsia has presented two projects.

The first project is aimed at developing the production of mRNA vaccines with a capacity of 100 million doses per year. The goal of the project is to reduce dependence on imported vaccines, and during pandemics, to supply them abroad.

To implement this project, Darnytsia is ready to attract $268 million in debt financing.

The second project, presented by Darnytsia in Berlin, is the construction of production of active pharmaceutical ingredients for supply to EU countries. Such a plant will contribute to the diversification of supplies and reduce Europe’s dependence on India and China in this regard. $107.7 million is needed to implement this project.

Both projects have passed the concept completion phase.

Darnytsia together with other leading companies in their fields was presented at the ‘Iron Heart. Iron Heart of the Ukrainian Economy’ installation. With the help of it, the participants of the conference had the opportunity to virtually enter the production of Darnytsia and assess the scale of the company’s work.

‘I am glad to join the Ukraine Recovery Conference 2024 and talk about the possibilities of Darnytsia, because it is the only pharmaceutical company in Ukraine that is recognized by the WHO as a production site for mRNA vaccines,” Anna Zakharash, a member of the Board of Directors of Darnytsia Pharmaceutical Company, said.

Photo: Delo.ua

Share:
Specialized edition for medical institutions and doctors.